Vivos Therapeutics Inc. Common Stock (VVOS)
FairStock Score: 26/100 — RISKY
Key Financials
| Current Price | $0.13 |
| Market Cap | $3M |
| P/E Ratio | -0.07 |
| ROE | -8,585.26% |
| Dividend Yield | 0% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I approach this as a Graham-style balance-sheet question first. Vivos sells a non-invasive, non-surgical, non-pharmaceutical treatment for dentofacial abnormalities, obstructive sleep apnea, and snoring, and revenue is moving: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $5.2M versus $3.8M in fiscal Q2 2025. For fiscal year 2025, revenue was $17.4M, but net income was -$21.2M, worse than -$11.1M in fiscal year 2024. In fiscal Q2 2026, net income was -$5.5M on $5.2M of revenue. That is not a business with a durable moat yet; it is a small, cash-consuming medical device and services model. Financial health is poor: trailing free cash flow is -$19.0M, FCF yield is -721.4% on a $2.6M market cap, Altman Z-score is -9.22, and FairStock ROE is -8585.26%. The Piotroski F-score is 4/9. At the 2026-10-26 close of $0.13, FairStock calculations show P/E of -0.07 and P/B of 2.07, so the low price is not statistically cheap against positive earnings—there are none. The Lynch category is none because of losses in each of the last four years. Growth is real but unprofitable. I see speculative optionality, not a margin-of-safety investment.
In plain English: Vivos Therapeutics makes non-surgical treatments for sleep apnea and snoring. The business looks weak because it keeps losing money and burning cash. At $0.13, the price looks very low compared with sales, but it is hard to call it cheap when there are no profits.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash
Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer